New drug shows promise for rare stomach cancer in chinese patients
NCT ID NCT05381753
First seen Feb 11, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tested the safety and effectiveness of avapritinib in 61 Chinese patients with a rare stomach cancer called GIST. Researchers monitored side effects and dose adjustments in real-world settings. The goal was to see how well the drug works outside of strict clinical trial conditions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL STROMAL TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beijing Cancer Hospital
Beijing, Beijing Municipality, 100000, China
Conditions
Explore the condition pages connected to this study.